Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response of Concomitant Vivotif and Dukoral Vaccines
NCT06104345Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Countries
- 1
- Sponsor
- Helsinki University Hospital
- Modality
- Vaccines & Immunotherapeutics
- Conditions
- typhoid fevercholera
01
Overview
Phase 4, randomised, open-label trial in typhoid fever and cholera comparing Vivotif, Dukoral and Dukoral+Vivotif (3 arms). Primary endpoint: Magnitude of antigen-specific plasmablast responses to oral typhoid fever and cholera vaccines. Started Oct 2023; status: completed.
02
Design
3 arms- Study design
- RandomizedOpen-label
Vivotif
Three oral doses of typhoid fever vaccine (Vivotif) on Days 0, 2 and 4.
Dukoral
Two oral doses of cholera vaccine (Dukoral) on Days 0 and 7.
Dukoral+Vivotif
Oral typhoid fever and cholera vaccines administered simultaneously according to their schedules.
03
Who it enrols
Healthy volunteers aged 18-65 without recent typhoid/cholera vaccination or antibiotic/immunosuppressant use.
04
Endpoints
Primary
Magnitude of antigen-specific plasmablast responses to oral typhoid fever and cholera vaccines
Secondary
Titer of antigen-specific antibodies in lymphocyte supernatants (ALS)
Beyond the preview
Go deeper on NCT06104345.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104345.